Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Core Insights - The interview features Acumen Pharmaceuticals CEO Daniel O'Connell and Dr. Jessica Clark discussing the impact of Alzheimer's Disease and the company's focus on developing targeted therapies [1][5]. Industry Overview - In the U.S., over six million people are diagnosed with active Alzheimer's, and globally, the number is approximately 55 million [2]. - The economic burden of Alzheimer's treatment and long-term care is around $360 billion, excluding caregiver time and productivity losses [2]. Company Focus - Acumen Pharmaceuticals is dedicated to developing therapeutics specifically for Alzheimer's, with a focus on the monoclonal antibody sabirnetug, which targets amyloid beta oligomers (AβOs) [3][6]. - The company is advancing sabirnetug into a Phase II study involving about 540 patients across the U.S., North America, and Europe, with enrollment expected to be completed in the first half of the year [4][6]. Clinical Development - Positive results from the Phase I study of sabirnetug indicated a good safety profile and expected pharmacological effects on AβOs [3]. - The ongoing Phase II clinical trial, ALTITUDE-AD, targets early symptomatic Alzheimer's disease patients following the success of the Phase I trial, INTERCEPT-AD [6].